4//SEC Filing
Arcadia Biosciences, Inc. 4
Accession 0001209191-15-045956
$RKDACIK 0001469443operating
Filed
May 21, 8:00 PM ET
Accepted
May 22, 1:34 PM ET
Size
18.6 KB
Accession
0001209191-15-045956
Insider Transaction Report
Form 4
Shupp Darby E
Director10% Owner
Transactions
- Purchase
Common Stock
2015-05-20$8.00/sh+1,000,000$8,000,000→ 1,160,714 total(indirect: By Moral Compass Corporation) - Conversion
Series A Convertible Preferred Stock
2015-05-20−60,681,805→ 0 total(indirect: By Moral Compass Corporation)→ Common Stock (15,170,451 underlying) - Conversion
Series C Convertible Preferred Stock
2015-05-20−9,345,794→ 0 total(indirect: By Moral Compass Corporation)→ Common Stock (2,336,448 underlying) - Conversion
Common Stock
2015-05-20+15,170,451→ 16,331,165 total(indirect: By Moral Compass Corporation) - Conversion
Common Stock
2015-05-20+2,336,448→ 22,515,364 total(indirect: By Moral Compass Corporation) - Conversion
Series B Convertible Preferred Stock
2015-05-20−15,391,006→ 0 total(indirect: By Moral Compass Corporation)→ Common Stock (3,847,751 underlying) - Conversion
Common Stock
2015-05-20+3,847,751→ 20,178,916 total(indirect: By Moral Compass Corporation)
Footnotes (4)
- [F1]Ms. Shupp is the CFO of Moral Compass Corporation. Moral Compass Corporation is owned by the John G. Sperling 2012 Irrevocable Trusts No. 1, 2 and 3. Ms. Shupp serves as one of three trustees of the Sperling trusts; these trustees share voting and investment power over the shares held by Moral Compass Corporation.
- [F2]The Series A Convertible Preferred Stock converted into the Issuer's common stock at a conversion ratio of one share of common stock for every four shares of preferred stock upon the closing of the Issuer's initial public offering of common stock, and had no expiration date. This conversion ratio reflected an adjustment due to the Issuer's 1-for-4 reverse stock split effected on May 8, 2015.
- [F3]The Series B Convertible Preferred Stock converted into the Issuer's common stock at a conversion ratio of one share of common stock for every four shares of preferred stock upon the closing of the Issuer's initial public offering of common stock, and had no expiration date. This conversion ratio reflected an adjustment due to the Issuer's 1-for-4 reverse stock split effected on May 8, 2015.
- [F4]The Series C Convertible Preferred Stock converted into the Issuer's common stock at a conversion ratio of one share of common stock for every four shares of preferred stock upon the closing of the Issuer's initial public offering of common stock, and had no expiration date. This conversion ratio reflected an adjustment due to the Issuer's 1-for-4 reverse stock split effected on May 8, 2015.
Documents
Issuer
Arcadia Biosciences, Inc.
CIK 0001469443
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001469443
Filing Metadata
- Form type
- 4
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 1:34 PM ET
- Size
- 18.6 KB